Virtual 2021 Satellite symposia

Satellite Symposia

SATELLITE SYMPOSIA

nAMD Treatment Fundamentals: Keys to a Proactive and Individualized Anti-VEGF Treatment Approach for nAMD Patients

9 September, 14:00 CEST

Chairperson(s): A. Loewenstein ISRAEL & N. Eter GERMANY

Details

nAMD Treatment Fundamentals: Keys to a Proactive and Individualized Anti-VEGF Treatment Approach for nAMD Patients

Chairperson(s): A. Loewenstein ISRAEL & N. Eter GERMANY
Speakers:
Presentations:
Speakers and presentations:
A. Loewenstein ISRAEL
14:00 Welcome & ARS
N. Eter GERMANY
14:02 Review of EURETINA nAMD clinical trends survey data
S. Waldstein AUSTRIA
14:07 Diagnostic imaging and how to track nAMD disease progression with current technology
V. Chaudhary CANADA
14:16 Updates to Anti-VEGF treatment dosing and duration – impact on treatment protocols
J.F Korobelnik FRANCE
14:25 Balancing visual outcome goals vs. diagnostic outcome data – what’s the more important metric?
A. Loewenstein ISRAEL
14:34 Final ARS, live Q&A and panel discussion
 
14:45 End of Session
 

Beyond VEGF: Targeting the Ang-Tie Pathway for the Management of Retinal Diseases

9 September, 18:45 CEST

Chairperson(s): P. Schlottmann ARGENTINA

Details

Beyond VEGF: Targeting the Ang-Tie Pathway for the Management of Retinal Diseases

Chairperson(s): P. Schlottmann ARGENTINA
Speakers:
Presentations:
Speakers and presentations:
P. Schlottmann ARGENTINA | A. Joussen GERMANY | J. Monés SPAIN
18:45 Impact of anti-VEGF therapies and future perspectives; Advancing our understanding of the angiopoietin pathway; Targeting the Ang-Tie pathway; Phase 3 clinical evidence; Anti-inflammatory and anti-fibrotic effects of dual Ang-2/VEGF-A inhibition
P. Schlottmann ARGENTINA | A. Joussen GERMANY | J. Monés SPAIN
19:30 Live Q&A
 
19:45 End of Session
 

The Big Picture in Clinical Practice

10 September, 11:00 CEST

Chairperson(s): A. Loewenstein ISRAEL

Details

The Big Picture in Clinical Practice

Chairperson(s): A. Loewenstein ISRAEL
Speakers:
Presentations:
Speakers and presentations:
A. Loewenstein ISRAEL
11:00 Welcome & Introduction
L. Kodjikian FRANCE
11:05 Consensus papers on the use of a corticosteroid in DME and the Delphi approach
J. Zarranz-Ventura SPAIN
11:25 Suitable naïve versus pre-treated DME patients
A. Loewenstein ISRAEL
11:35 Q&A
 
11:45 End of Session
 

Clinical Perspectives on nAMD Management: Making Informed Decisions Along the Patient Journey

10 September, 11:00 CEST

Chairperson(s): A. Koh SINGAPORE

Details

Clinical Perspectives on nAMD Management: Making Informed Decisions Along the Patient Journey

Chairperson(s): A. Koh SINGAPORE
Speakers:
Presentations:
Speakers and presentations:
A. Koh SINGAPORE
11:00 Welcome and introduction to nAMD​
R. Khoramnia GERMANY
11:05 Managing my nAMD patients: making informed decisions at therapy initiation​
A. Khanani USA
11:15 Managing nAMD: making informed decisions along the patient journey​
All Faculty
11:30 Q&A
A. Koh SINGAPORE
11:40 Concluding remarks​ 
 
11:45 Session Ends
 

Exploring New Retina Technologies and Beyond

10 September, 11:00 CEST

Chairperson(s): C. Mateo SPAIN

Details

Exploring New Retina Technologies and Beyond

Chairperson(s): C. Mateo SPAIN
Speakers:
Presentations:
Speakers and presentations:
A. Chandra UK
11:00 Bi-Blade™ and bimanual surgery
Y. Le Mer FRANCE
11:10 Experience with the latest generation Vitesse®​
B. Parolini ITALY
11:20 Management of complex cases with B+L technology
C. Mateo SPAIN
11:30 How would you do that? Panel discussion on interesting case studies
 
11:45 Session Ends
 

Restoring Vision in Advanced AMD: A Roundtable Discussion on Treatment Options

10 September, 11:00 CEST

Chairperson(s): J. Talamo USA

Details

Restoring Vision in Advanced AMD: A Roundtable Discussion on Treatment Options

Chairperson(s): J. Talamo USA
Speakers:
Presentations:
Speakers and presentations:
D. Keegan Ireland
11:00 Overview of treatment options
A. Augustin Germany
11:05 Discussion 
W. Sekundo Germany
11:05 Discussion
J. Silvestri Ireland
11:05 Discussion
 
11:45 Session Ends
 

A Pathway to Enhanced Care for Inherited Retinal Dystrophy Patients

10 September, 14:00 CEST

Chairperson(s): B.P. Leroy BELGIUM

Details

A Pathway to Enhanced Care for Inherited Retinal Dystrophy Patients

Chairperson(s): B.P. Leroy BELGIUM
Speakers:
Presentations:
Speakers and presentations:
 
14:00 Alessia’s story
B.P. Leroy BELGIUM
14:03 Welcome and introduction perspective
N. Oluonye UK
14:06 The child behind the eye
C. Boon THE NETHERLANDS
14:08 Redefining the standard of care for pediatric and adult IRD patients
M. Moosajee UK
14:16 A multidisciplinary approach to diagnosing and treating IRDs
R. Ba-Abbad SAUDI ARABIA 
14:24 Unlocking the IRD genetic code
K. Klemp DENMARK
14:32 The treatment experience: a vitreoretinal surgeon’s perspective
All Faculty
14:35 The importance of ongoing patient follow-up
B.P. Leroy BELGIUM
14:43 Summary and close
 
11:45 Session Ends
 

The Ophthalmology Clinic of 2030: What is on the Horizon?

10 September, 14:00 CEST

Chairperson(s): M. de Smet SWITZERLAND

Details

The Ophthalmology Clinic of 2030: What is on the Horizon?

Chairperson(s): M. de Smet SWITERLAND
Speakers:
Presentations:
Speakers and presentations:
A. Loewenstein ISREAL
14:00 Can we have an ophthalmology clinic at home?
H. Bogunović AUSTRIA 
14:06 How can AI help us and our patients?
P. Lanzetta ITALY
14:12 How can we optimize our existing treatments? & Can we treat at home?
M. Pennesi USA
14:24 How can we treat the uncurable?
P. Bussfeld SWITZERLAND/ GERMANY 
14:34 What is Bayer’s role in the future of ophthalmology?
 
11:45 Session Ends
 

AMD and DME Treatment Innovations: Home Monitoring, Artificial Intelligence Diagnostics and Extended Duration Anti-VEGF Therapeutics

10 September, 14:00 CEST

Chairperson(s): A. Loewenstein ISRAEL

Details

AMD and DME Treatment Innovations: Home Monitoring, Artificial Intelligence Diagnostics and Extended Duration Anti-VEGF Therapeutics

Chairperson(s): A. Loewenstein ISREAL
Speakers:
Presentations:
Speakers and presentations:
A. Loewenstein ISREAL
14:00 Welcome, ARS & review of EURETINA AMD & DME clinical trends survey data
S. Wolf SWITZERLAND 
14:05 The Anti-VEGF treatment burden
R. Tadayoni FRANCE
14:13 Current and future applications of longer lasting Anti-VEGF therapeutics
C. Awh USA
14:21 Insights and pearls on implantable sustained release technologies
A. Loewenstein ISREAL
14:29 Artificial Intelligence (AI) in nAMD & DME treatment decision-making
A. Loewenstein ISREAL
14:37 Final ARS, live Q&A and panel discussion
 
14:45 Session Ends
 

DME Management: Challenges and Opportunities

10 September, 18:00 CEST

Chairperson(s): T. Wong SINGAPORE

Details

DME Management: Challenges and Opportunities

Chairperson(s): T. Wong SINGAPORE
Speakers:
Presentations:
Speakers and presentations:
T. Wong SINGAPORE
18:00 Welcome and introduction​
C. Creuzot-Garcher FRANCE
18:05 Unmet needs and challenges and opportunities in the current management of DME
N. Eter GERMANY
18:15 Why fluid matters in DME
C. Wykoff USA
18:25 Latest evidence from an advanced clinical development program perspective
T. Wong SINGAPORE
18:40 Summary
All Faculty
18:45 Live discussion with Q&A
T. Wong SINGAPORE
18:59 Meeting close
 
19:00 Session Ends
 

Geographic Atrophy: What Have we Learnt and What is Still to be Discovered?

10 September, 18:00 CEST

Chairperson(s): F.G. Holz GERMANY

Details

Geographic Atrophy: What Have we Learnt and What is Still to be Discovered?

Chairperson(s): F.G. Holz GERMANY
Speakers:
Presentations:
Speakers and presentations:
F.G. Holz GERMANY
18:00 Introduction​
R. Tadayoni FRANCE
18:03 Expanding our knowledge in GA
All Faculty
18:13 Live Panel Discussion
F.G. Holz GERMANY
18:18 Emerging clinical data in GA
All Faculty
18:28 Live Panel Discussion
J. Monés SPAIN
18:33 Continued evolution of our understanding of AMD and the role of new vessels
All Faculty
18:43 Live Panel Discussion
F.G. Holz GERMANY
18:48 Summary and close
 
18:50 Session Ends
 

Optimising nAMD Management Through Longer-acting Therapies

10 September, 18:00 CEST

Chairperson(s): A. Laidlaw UK

Details

Optimising nAMD Management Through Longer-acting Therapies

Chairperson(s):A. Laidlaw UK
Speakers:
Presentations:
Speakers and presentations:
A. Laidlaw UK
18:00 Welcome and opening remarks
A. Laidlaw UK
18:01 Addressing the unmet need for longer-acting therapies for nAMD
N. Holekamp USA
18:09 Continuous delivery of anti–VEGF-A
A. Laidlaw UK
18:19 Summary
A. Laidlaw UK & N. HolekampUSA
18:20 - 18:40 Panel Discussion
 
18:40 Session Ends
 

Looking into the Future: nAMD Detection and Progression

10 September, 18:00 CEST

Chairperson(s): A. Loewenstein ISRAEL

Details

Looking into the Future: nAMD Detection and Progression

Chairperson(s): A. Loewenstein ISREAL
Speakers:
Presentations:
Speakers and presentations:
N. Bressler USA
18:00 Looking into the future: predicting progression in nAMD
A. Loewenstein ISREAL
18:11 Looking into the future: remote monitoring
S. Sadda USA
18:22 Looking into the future: imaging in nAMD
 
18:50 Session Ends
 

Controversies in Laser Treatments in 2021

10 September, 18:00 CEST

Chairperson(s): P. Stanga UK

Details

Controversies in Laser Treatments in 2021

Chairperson(s): P. Stanga UK
Speakers:
Presentations:
Speakers and presentations:
V. Chong UK
18:00 Macular laser photocoagulation: still relevant in 2021?
L. Wu COSTA RICA
18:15 Anti-VEGF vs Laser for PDR, a changing treatment paradigm?
P. Stanga UK
18:30 Diagnosis, classification and management options for vitreous opacities
 
18:50 Session Ends
 

Digital Innovations: Jumping from Concepts to the Clinic

11 September, 11:00 CEST

Chairperson(s): N. Bressler USA

Details

Digital Innovations: Jumping from Concepts to the Clinic

Chairperson(s): N. Bressler USA
Speakers:
Presentations:
Speakers and presentations:
N. Bressler USA
11:00 Welcome and Open
A. Loewenstein ISRAEL
11:05 Clinical endpoint collection outside of the office
P. Keane UK
11:15 Artificial intelligence: why hasn’t it jumped to the clinic yet?​
All Faculty
11:25 Panel discussion and Q&A
N. Bressler USA
11:40 Summary and close
 
11:45 End of Session
 

Maximizing Treatment Benefits for our Patients with Retinal Vascular Diseases

11 September, 11:00 CEST

Chairperson(s): J. Kitchens USA

Details

Maximizing Treatment Benefits for our Patients with Retinal Vascular Diseases

Chairperson(s): J. Kitchens USA
Speakers:
Presentations:
Speakers and presentations:
V. Chaudhary CANADA 
11:00 Maximizing vision outcomes in DME: is baseline VA only one piece of the puzzle?
J. Garweg SWITZERLAND 
11:10 Durability that lasts: proactive, extended dosing in retinal vascular disease
A. Chang AUSTRALIA 
11:20 Aflibercept in the real-world: what’s the bigger picture?
T. Langmann GERMANY 
11:27 Understanding the target: what are we aiming for?
 
11:35 End of Session
 

Evolution in Surgical Techniques - The Modern VR Procedure

11 September, 11:00 CEST

Chairperson(s): R. Tadayoni FRANCE

Details

Evolution in Surgical Techniques - The Modern VR Procedure

Chairperson(s): R. Tadayoni FRANCE
Speakers:
Presentations:
Speakers and presentations:
R. Tadayoni FRANCE
11:00 Welcome and introduction to nAMD​
D. Chow CANADA
11:01 The shovel and cut technique: management of complex diabetic retinopathy in 25G surgery
S. Rizzo ITALY
11:15 Speed and stability: rethinking 27G surgery
R. Tadayoni FRANCE
11:29  Panel Discussion
B. Delas SPAIN
11:29 Panel Discussion
F. Barca ITALY
11:29 Panel Discussion
T. Ivonova UK
11:29 Panel Discussion
 
11:35 End of Session
 

Best-informed Decision Making – Latest Innovations in Retinal Imaging and Surgical Visualization

11 September, 11:00 CEST

Chairperson(s): J.F Korobelnik FRANCE

Details

Best-informed Decision Making – Latest Innovations in Retinal Imaging and Surgical Visualization

Chairperson(s): J.F. Korobelnik FRANCE
Speakers:
Presentations:
Speakers and presentations:
J.F. Korobelnik FRANCE
11:00 Advancements in multi-modal imaging
R. Tadayoni FRANCE
11:07 Visualization from multi-modal imaging in the clinic to 3D in the OR
L-O Hattenbach GERMANY
11:19 Changing paradigms - real-time OCT guided approaches to vitreoretinal surgery
All Faculty
11:26 Panel Discussion
 
11:45 End of Session
 

Managing Patients with Diabetic Macular Edema Through the Pandemic and Beyond: Discussing Ongoing Strategies

11 September, 14:00 CEST

Chairperson(s): R. Tadayoni FRANCE

Details

Managing Patients with Diabetic Macular Edema Through the Pandemic and Beyond: Discussing Ongoing Strategies

Chairperson(s): R. Tadayoni FRANCE
Speakers:
Presentations:
Speakers and presentations:
R. Tadayoni FRANCE
11:00 Welcome and introduction
R. Tadayoni FRANCE
11:03 Managing DME: understanding the challenges​ | DME and COVID-19: what have we learnt?​ | What will last beyond the pandemic: ongoing strategies ​
S. Sivaprasad UK
11:03 Managing DME: understanding the challenges​ | DME and COVID-19: what have we learnt?​ | What will last beyond the pandemic: ongoing strategies ​
P. Schlottmann ARGENTINA
11:03 Managing DME: understanding the challenges​ | DME and COVID-19: what have we learnt?​ | What will last beyond the pandemic: ongoing strategies ​
All Faculty
14:27 Panel discussion: Q&A​
R. Tadayoni FRANCE
14:42Summary and close​
 
End of Session
 

Flexibility and Long-term Predictability: Unlocking the Potential of Q16 Dosing for your Patients

11 September, 14:00 CEST

Chairperson(s): D. Wong CANADA

Details

Flexibility and Long-term Predictability: Unlocking the Potential of Q16 Dosing for your Patients

Chairperson(s): D. Wong CANADA
Speakers:
Presentations:
Speakers and presentations:
N. Holekamp USA
14:00 Fluid in nAMD: a pragmatic approach
J. Zarranz-Ventura SPAIN
14:10 Maintaining function with flexible treatment intervals up to Q16
TBC
14:20 Not just a case study: real-world outcomes with aflibercept
M. Stewart USA
14:28 Making sense of molecular properties
 
End of Session
 

Amgen: Spotlight on Real-world Considerations for Biosimilars in Ophthalmology

11 September, 14:00 CEST

Chairperson(s): J. Franklin USA

Details

Amgen: Spotlight on Real-world Considerations for Biosimilars in Ophthalmology

Chairperson(s): J. Franklin USA
Speakers:
Presentations:
Speakers and presentations:
J. Franklin USA
14:00 Spotlight on real-world considerations for biosimilars in ophthalmology
D. Sarraf USA
14:00 Spotlight on real-world considerations for biosimilars in ophthalmology
J. Franklin USA
14:30 Q&A
D. Sarraf USA
14:30 Q&A
 
14:45 End of Session
 

AMD Fluid Resolution: Optimizing Real-world Outcomes in nAMD Treatment

11 September, 18:15 CEST

Chairperson(s): F.G. Holz GERMANY

Details

AMD Fluid Resolution: Optimizing Real-world Outcomes in nAMD Treatment

Chairperson(s): F.G. Holz GERMANY
Speakers:
Presentations:
Speakers and presentations:
F.G. Holz GERMANY
18:15 Welcome, ARS and review of EURETINA AMD clinical trends survey data
S. Wolf SWITZERLAND
18:20 Best practices for diagnosing & monitoring AMD
N. Eter GERMANY
18:30 nAMD patient selection and outcome goals for Anti-VEGF treatment
R. Tadayoni FRANCE
18:40 nAMD treatment protocols and therapy decisions
R. Singh USA
18:50 Real-world experience with new Anti-VEGFs
F.G. Holz GERMANY
19:00 Final ARS & panel discussion
 
19:15 End of Session
 

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2022 Hamburg

Opportunities

Memberships

Forum

About

Privacy Policy

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 

Follow us

© EURETINA 2021 All rights reserved